In the case of intra-tumor heterogeneity, with HER2-positive and HER2-negative sub-clones, it is likely that targeted therapies will clear off HER2-positive cells, but not eradicate the tumor, which will relapse as HER2-negative. This evidence concerns the gene ERBB2 and neoplasm.